GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
0
Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics
https://www.zacks.com/stock/news/2217012/countdown-to-merck-mrk-q4-earnings-wall-street-forecasts-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2217012
Jan 29, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
0
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/01/28/a-bull-market-is-here-2-stocks-to-buy-and-hold-for/?source=iedfolrf0000001
Jan 28, 2024 - These companies can perform well through this bull run and beyond.
0
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
https://www.zacks.com/stock/news/2215849/merck-mrk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215849
Jan 25, 2024 - Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
Q4 Earnings Season Scorecard and Fresh Analyst Reports for Amazon, Home Depot & Merck
https://www.zacks.com/commentary/2214056/q4-earnings-season-scorecard-and-fresh-analyst-reports-for-amazon-home-depot-merck?cid=CS-ZC-FT-research_daily-2214056
Jan 23, 2024 - Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.
0
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
0
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
0
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
https://www.zacks.com/stock/news/2207963/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2207963
Jan 09, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
0
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
https://www.zacks.com/stock/news/2207538/corcept-cort-stock-rises-on-upbeat-revenue-guidance-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207538
Jan 09, 2024 - Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
0